The TNM lung cancer staging system is primarily utilized for non-small-cell lung cancer (NSCLC), which accounts for approximately 75% of lung cancer diagnoses.
肺癌的TNM系统最初用于非小细胞癌(NSCLC)，这种癌大约占所有肺癌的75%。
Objective to investigate the expression of COX-2 and its relation to clinical pathophysiological features and prognosis in non-small cell lung cancer (NSCLC).
目的探讨非小细胞肺癌组织中COX 2的表达情况及其与患者临床病理生理特征和预后的关系。
Medical oncologists are faced with multiple factors to consider when staging a patient with suspected or confirmed non-small cell lung cancer (NSCLC).
肿瘤病学家在对可疑或确诊的非小细胞肺癌患者进行分期时要面临多方面因素的考量。
应用推荐